MiDAS II (Mild® Decompression Alternative to Open Surgery): Vertos Mild Patient Evaluation Study

Vertos Medical, Inc.55 enrolled

Overview

This is a multi-center, prospective, patient outcomes assessment of Minimally Invasive Lumbar Decompression with the Mild® devices in patients with symptomatic central canal spinal stenosis.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lumbar Spinal Stenosis

Interventions

lumbar decompressionPROCEDURE

The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Symptomatic lumbar spinal stenosis (LSS) primarily caused by dorsal element hypertrophy. * Prior failure of conservative therapy and Oswestry Disability Index (ODI) score \> 20%. * Radiologic evidence of lumbar spinal stenosis (LSS), ligamentum flavum hypertrophy (typically \> 2.5 mm), confirmed by pre-op MRI and/or CT. * Central canal cross sectional area clearly reduced per MRI/CT report. * If present, anterior listhesis preferred ≤ 5.0mm and deemed stable by Investigator. * Able to walk at least 10 feet unaided before being limited by pain. * Available to complete 26 weeks of follow-up. * A signed Informed Consent Form is obtained from the patient. * Adults at least 18 years of age. Exclusion Criteria: * Prior surgery at intended treatment level. * Compound fracture with interspinal retropulsion contributing to spinal stenosis. * Disabling back or leg pain from causes other than LSS (e.g. acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.). * Disc protrusion or osteophyte formation severe enough to confound study outcome. * Facet hypertrophy severe enough to confound study outcome. * Bleeding disorders and/or current use of anti-coagulants. * Use of acetylsalicylic acid (ASA) and/or non-steroidal anti-inflammatory drug (NSAID) within 5 days of treatment. * Epidural steroid administration within prior three weeks (of procedure). * Inability of the patient to lie prone for any reason with anesthesia support (e.g.chronic obstructive pulmonary disease (COPD), obesity, etc.). * Metabolic wound healing pathologies deemed by Investigator to compromise study outcomes. * Dementia and/or inability to give informed consent. * Pregnant and/or breastfeeding. * On Workman's Compensation or considering litigation associated with back pain.

Locations (8)

Space Coast Pain Institute

Merritt Island, Florida, United States

The Spine Center

Baltimore, Maryland, United States

Occupational and Pain Management Professionals

Festus, Missouri, United States

Lab2Marche, LLC

Las Vegas, Nevada, United States

Outcomes

Primary Outcomes

Changes in Back Pain as Measured by a 10-point Visual Analog Scale (VAS).

The 10-point Visual Analog Scale (VAS)rates 'no pain' as zero and 'worst pain imaginable' as ten. VAS mean improvement greater than or equal to 2 points is considered clinically relevant. The change from baseline to Month 6 is presented below where a positive value represents the baseline value minus the 6 month value.

Time frame: Baseline and Month 6

Function as Measured Subjectively by the Oswestry Disability Index Questionnaire

Oswestry Disability Index (ODI) measures permanent functional disability using questions regarding activities of daily living (ADL), specifically disturbance of ADL related to chronic back pain. Higher scores indicate a 'more limited' life. The ten topics of the ODI are rated from zero (no pain/limitation) to five (high pain/very limited physically). The worst possible score is 50 (100% disability) with the best score being zero (0% disability).Change from baseline to 6 months is presented below, where a positive value represents the baseline value minus the 6 month value.

Time frame: Baseline and Month 6

Quality of Life Changes as Determined by Short Form 12-question (SF-12) Survey Specifically Related to Physical Component Score (PCS).

The SF-12 is a validated norm-based scoring tool used to determine treatment outcomes. The PCS summary measure shows the impact of the treatment on the patients abilities to conduct their usual physical activities. Clinical relevance of PCS is established by baseline to post-treatment improvement of 2 to 3 points. Norm-based scoring is used so that each scale has the same mean (50 points) and the same standard deviation (10 points) as the general US population in 1998. Scores below 50 indicate a decline in health status, with lower scores representing worse health status. Minimally Important Difference (MID) is a measure of true clinical relevance of a difference, with suggested MID for the Physical Component Summary (PCS) being 2 to 3 points. Change from baseline to 6 months is presented, where a positive value represents the 6 month value minus the baseline value.

Time frame: Baseline and Month 6

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.